| Literature DB >> 29850607 |
Joanna Gołębiewska1, Andrzej Olechowski1, Marta Wysocka-Mincewicz2, Marta Baszyńska-Wilk2, Artur Groszek2, Agnieszka Czeszyk-Piotrowicz1, Mieczysław Szalecki2,3, Wojciech Hautz1.
Abstract
AIM: To assess the retinal and choroidal thickness and ganglion cell complex (GCC) in pubescent children with type 1 diabetes (T1D) without diabetic retinopathy (DR), using spectral domain optical coherence tomography (SD-OCT). MATERIALS ANDEntities:
Mesh:
Year: 2018 PMID: 29850607 PMCID: PMC5903202 DOI: 10.1155/2018/5458015
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1The ganglion cell complex scan pattern (7 × 7 mm) consists of 15 vertical and 1 horizontal scan lines.
Figure 2An example of horizontal macular OCT cross section in a T1D patient. The GCC thickness is automatically measured as the distance between the ILM and the outer IPL boundary.
Study sample characteristics.
| Variable |
| SD | 95% CI | Min.–max. |
|---|---|---|---|---|
| Age (years) | ||||
| Diabetic patients | 15.3 | 2.2 | 14.7–15.8 | 11.3–18.5 |
| Diabetes duration (years) | 6.3 | 3.4 | 5.5–7.2 | 1.0–14.4 |
| Age at onset (years) | 8.9 | 3.8 | 8.0–9.0 | 2.3–16.5 |
| Glycated hemoglobin − actual level (%) | 8.2 | 1.2 | 7.9–8.5 | 6.4–13.3 |
| Glycated hemoglobin − mean level (%) | 8.1 | 1.1 | 7.8–8.3 | 6.3–11.6 |
| Actual level of daily urine albumin excretion (mg/d) | 10.3 | 6.9 | 8.5–12.2 | 0.5–33.3 |
| Mean level of daily urine albumin excretion (mg/d) | 8.9 | 8.1 | 6.7–11.1 | 0.5–40.5 |
| Serum creatinine (mg/dL) | 0.69 | 0.16 | 0.65–0.73 | 0.42–1.12 |
| Daily urine creatinine excretion (mg/d) | 1.29 | 0.95 | 1.01–1.58 | 0.27–5.47 |
| Systolic blood pressure (mmHg) | 114 | 10.8 | 111.0–116.9 | 84–140 |
| Diastolic blood pressure (mmHg) | 68 | 10.5 | 65.3–71.1 | 40–91 |
M: mean; SD: standard deviation; CI: confidence interval.
Descriptive statistics for choroidal thickness (CT, μm) in individual retinal quadrants (diabetic patients versus nondiabetic).
| Variable | Study group |
| SD | 95% CI | Range |
|
|---|---|---|---|---|---|---|
| Central choroidal thickness, CT ( | Diabetic | 355.65 | 77.50 | 335.09–376.21 | 187–585 | 0.081 |
| Nondiabetic | 327.98 | 66.02 | 307.66–248.29 | 179–479 | ||
| CT—nasal quadrant ( | Diabetic | 282.32 | 76.59 | 261.99–302.64 | 138–542 | 0.427 |
| Nondiabetic | 267.16 | 68.68 | 246.03–288.30 | 130–398 | ||
| CT—temporal quadrant ( | Diabetic | 338.88 | 71.18 | 319.99–357.76 | 190–515 | 0.338 |
| Nondiabetic | 324.07 | 70.17 | 302.47–345.66 | 155–512 | ||
| CT—superior quadrant ( | Diabetic | 342.40 | 76.48 | 321.72–363.08 | 149–534 | 0.418 |
| Nondiabetic | 328.70 | 70.11 | 307.12–350.27 | 169–453 | ||
| CT—inferior quadrant ( | Diabetic | 352.35 | 82.17 | 330.13–374.56 | 185–599 | 0.813 |
| Nondiabetic | 354.56 | 78.15 | 330.51–378.61 | 184–539 |
M: mean; SD: standard deviation; CI: confidence interval.
Figure 3Central tendency and dispersion for the choroidal thickness (μm) in selected retinal quadrants in the study sample by T1D status and gender.
Descriptive statistics of GCC parameters in the studied patients by presence of type 1 diabetes mellitus.
| Variable | Study group |
| SD | 95% CI | Range |
|
|---|---|---|---|---|---|---|
| Ganglion cell complex—total | Diabetic | 97.51 | 6.77 | 95.77–99.24 | 80.97–118.39 | 0.448 |
| Nondiabetic | 98.08 | 6.03 | 96.25–99.92 | 87.23–111.94 | ||
| GCC—superior quadrant | Diabetic | 96.05 | 10.45 | 93.38–98.73 | 30.88–117.00 | 0.371 |
| Nondiabetic | 97.42 | 6.56 | 95.42–99.41 | 86.46–111.43 | ||
| GCC—inferior quadrant | Diabetic | 98.05 | 8.49 | 95.88–100.23 | 81.69–138.14 | 0.401 |
| Nondiabetic | 98.74 | 5.74 | 96.99-100.48 | 88.00–112.47 | ||
| Focal loss volume (%) | Diabetic | 0.512 | 0.756 | 0.313–0.711 | 0.000–4.420 |
|
| Nondiabetic | 0.275 | 0.434 | 0.142–0.407 | 0.000–2.202 | ||
| Global loss volume (%) | Diabetic | 2.349 | 2.926 | 1.580–3.118 | 0.000–14.402 | 0.282 |
| Nondiabetic | 1.842 | 1.909 | 1.262–2.422 | 0.003–8.265 |
M: mean; SD: standard deviation; CI: confidence interval.
Descriptive statistics foveal/parafoveal thickness (μm) and volume (mm3) in the studied patients by presence of type 1 diabetes mellitus.
| Variable | Study group |
| SD | 95% CI | Range |
|
|---|---|---|---|---|---|---|
| Foveal thickness ( | Diabetic | 257.82 | 21.37 | 252.44–263.21 | 200–308 |
|
| Nondiabetic | 262.63 | 20.07 | 256.45–268.80 | 221–324 | ||
| Parafoveal thickness ( | Diabetic | 315.90 | 17.95 | 311.38–320.42 | 270–360 |
|
| Nondiabetic | 325.26 | 15.37 | 320.47–330.05 | 289–360 | ||
| Foveal volume (mm3) | Diabetic | 0.202 | 0.017 | 0.198–0.207 | 0.157–0.242 |
|
| Nondiabetic | 0.206 | 0.016 | 0.201–0.211 | 0.173–0.254 | ||
| Parafoveal volume (mm3) | Diabetic | 1.985 | 0.112 | 1.957–2.014 | 1.698–2.261 |
|
| Nondiabetic | 2.043 | 0.096 | 2.013–2.073 | 1.818–2.261 |
∗Patient age and gender were considered in the multivariate analyses.
Figure 4Correlations between the level of glycated hemoglobin (HbA1c, %) and foveal/parafoveal thickness (μm) and volume (mm3) in the studied patients with type 1 diabetes mellitus.